Clinical trial
PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage…
NCT00276523 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00276523 |
|---|---|
| Title | PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery |
| Official title | A Randomized Phase II Study of SCH 54031 in Surgically Resectable Squamous Cell Tumors of the Head and Neck |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Biological, Procedure |
| Interventions | PEG-interferon alfa-2b, Conventional surgery, Neoadjuvant therapy |
| Enrollment | 3 |
| Start date | Feb 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Jan 13, 2006 |
| Last update posted | Oct 31, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: